Serum hyaluronic acid as a comprehensive marker to assess severity of liver disease in schistosomiasis

被引:34
作者
Köpke-Aguiar, LA
Martins, JRM
Passerotti, CC
Toledo, CF
Nader, HB
Borges, DR
机构
[1] Univ Fed Sao Paulo, Dept Med, Sao Paulo, Brazil
[2] Univ Fed Sao Paulo, Dept Biochem, Sao Paulo, Brazil
关键词
hyaluronic acid; schistosomiasis; liver fibrosis; portal hypertension; liver test;
D O I
10.1016/S0001-706X(02)00136-5
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Schistosomiasis mansoni is a non-cirrhotic fibrogenic disease model. The mild form shows normal liver function with slight or no liver fibrosis whereas in the periportal fibrosis form the manifestations of portal hypertension prevail over hepatocellular failure. We assessed serum hyaluronic acid as a marker of the course of the disease. We studied 24 patients presenting with pure chronic forms of schistosomiasis and seven with cirrhosis. In order to measure serum hyaluronic acid we developed a sandwich fluorescent ELISA-like assay. alpha(2)-Macroglobulin, prothrombin index, gamma-glutamyltransferase, platelets and ultrasound parameters were also assessed. The 20 mug/l (ROC plot) hyaluronic acid level differentiated patients with the mild form (with no portal hypertension) from those with the severe form of schistosomiasis with 78% diagnostic efficacy. The 80 mug/l cut-off value differentiated patients with the severe form of schistosomiasis from the cirrhotic group with similar diagnostic efficacy. alpha2-Macroglobulin provided no distinction between the groups studied. The hyaluronic acid serum concentration correlated positively with the splenic vein diameter (P = 0.004) and marginally with alpha2-macroglobulin (P = 0.059). Serum hyaluronic acid is a good marker for the initial phase of hepatic fibrosis and it was able to assess severity of liver disease in schistosomiasis. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:117 / 126
页数:10
相关论文
共 31 条
[11]   Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis [J].
Guéchot, J ;
Serfaty, L ;
Bonnand, AM ;
Chazouillères, O ;
Poupon, RE ;
Poupon, R .
JOURNAL OF HEPATOLOGY, 2000, 32 (03) :447-452
[12]   Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct [J].
Hammel, P ;
Couvelard, A ;
O'Toole, D ;
Ratouis, A ;
Sauvanet, A ;
Fléjou, JF ;
Degott, C ;
Belghiti, J ;
Bernades, P ;
Valla, D ;
Ruszniewski, P ;
Lévy, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (06) :418-423
[13]  
HASCALL VC, 1974, J BIOL CHEM, V249, P4232
[14]  
Hassanein HI, 1997, ARZNEIMITTEL-FORSCH, V47, P84
[15]   Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study [J].
Imbert-Bismut, F ;
Ratziu, V ;
Pieroni, L ;
Charlotte, F ;
Benhamou, Y ;
Poynard, T .
LANCET, 2001, 357 (9262) :1069-1075
[16]  
JACKSON AA, 2001, AM J PHYSIOL-GASTR L, V281, pG119
[17]   Diagnostic value of connective tissue metabolites in Schistosoma mansoni related liver disease [J].
Kardorff, R ;
Mugashe, C ;
Gabone, RM ;
Mahlert, C ;
Doehring, E .
ACTA TROPICA, 1999, 73 (02) :153-164
[18]   Proposed abdominal sonographic staging to predict severity of liver diseases - Analysis with peritoneoscopy and histology [J].
Khan, KN ;
Yamasaki, M ;
Yamasaki, K ;
Inoue, O ;
Yatsuhashi, H ;
Koga, M ;
Yano, M .
DIGESTIVE DISEASES AND SCIENCES, 2000, 45 (03) :554-564
[19]   ETHANOL CHALLENGE IN NONALCOHOLIC PATIENTS WITH SCHISTOSOMIASIS [J].
MARTINS, RD ;
BORGES, DR .
JOURNAL OF CLINICAL PATHOLOGY, 1993, 46 (03) :250-253
[20]   ALPHA-2-MACROGLOBULIN AND HEPATIC-FIBROSIS - DIAGNOSTIC INTEREST [J].
NAVEAU, S ;
POYNARD, T ;
BENATTAR, C ;
BEDOSSA, P ;
CHAPUT, JC .
DIGESTIVE DISEASES AND SCIENCES, 1994, 39 (11) :2426-2432